Reporting rates of rhabdomyolysis with statins to the FDA

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2002年 / 898卷 / 1期
关键词：
Statin; Digoxin; Simvastatin; Atorvastatin; Pravastatin;
D O I：
10.2165/00128415-200208980-00008
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [31] FDA Medical Products Reporting Program
    Waterworth C.
    Critical Care, 4 (1):
  • [32] Reporting Adverse Events for Cannabis to the FDA
    Hines, Michelle C.
    Harinstein, Lisa M.
    Kortepeter, Cindy M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 98 - 98
  • [33] FDA to oversee reporting of clinical trials
    Ratner, Mark
    NATURE BIOTECHNOLOGY, 2012, 30 (12) : 1163 - 1163
  • [34] Reporting veterinary drug shortages to the FDA
    不详
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2003, 222 (05): : 560 - 560
  • [35] Statins: FDA-Notes to the Diabetes and cognitive Disorders
    不详
    DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR, 2012, 55 (02): : 38 - 38
  • [36] REPORTING FREQUENCY OF QT-INTERVAL ABNORMALITIES IN THE FDA ADVERSE EVENT REPORTING SYSTEM (FDA_AERS)
    Raschi, E.
    Poluzzi, E.
    Koci, A.
    De Ponti, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 84 - 84
  • [37] Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database
    Deng, Bin
    Li, Shijun
    You, Ruxu
    Fu, Zhiwen
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [38] FDA adverse event reports on statin-associated rhabdomyolysis
    Omar, MA
    Wilson, JP
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (02) : 288 - 295
  • [39] Rhabdomyolysis with tetraparesis secondary to hepatitis E virus infection in a patient on statins
    Hanotte, B.
    Gaultier, J. B.
    Abravanel, F.
    Pozzetto, B.
    Feasson, L.
    Cathebras, P.
    REVUE DE MEDECINE INTERNE, 2022, 43 (04): : 252 - 255
  • [40] Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins
    Dorota Danielak
    Marta Karaźniewicz-Łada
    Franciszek Główka
    Drugs, 2018, 78 : 1105 - 1112
12345